Tissue-specific promoters in gene therapy for the treatment of prostate cancer

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

Delivery of therapeutic toxic genes to and their expression in tumor cells through the use of tissue-specific promoters could decrease their toxic effect on neighboring normal cells when virus-mediated gene delivery results in their infection. We have demonstrated the utility of two prostate cancer- specific promoters, long PSA and osteocalcin, for tissue-specific toxic gene therapy for prostate cancer. The two promoters were highly active in both androgen-dependent and androgen-independent prostate cancer cells. We also introduce the Phase I trial of osteocalcin promoter-based toxic gene therapy for bone metastases of prostate cancer, which is in progress at the University of Virginia.

Original languageEnglish (US)
Pages (from-to)73-82
Number of pages10
JournalMolecular Urology
Volume4
Issue number2
DOIs
StatePublished - Jan 1 2000

    Fingerprint

ASJC Scopus subject areas

  • Urology

Cite this

Shirakawa, T., Gotoh, A., Wada, Y., Kamidono, S., Ko, S. C., Kao, C., Gardner, T. A., & Chung, L. W. K. (2000). Tissue-specific promoters in gene therapy for the treatment of prostate cancer. Molecular Urology, 4(2), 73-82. https://doi.org/10.1089/10915360050138620